Multiple myeloma: open trials in Czechia

24 open trials have a site in Czechia. Registry data; only the trial team decides who can take part.

NCT07222761
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Trial Treatment · Phase 3 · Regeneron Pharmaceuticals
Fakultni nemocnice Brno, Brno · Fakultni nemocnice Hradec Kralove, Hradec Králové · Fakultni nemocnice Ostrava, Ostrava · Fakultni nemocnice Kralovske Vinohrady, Prague
Registry updated 2026-11-04
NCT05552222
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Fakultni nemocnice Brno, Brno · Fakultni Nemocnice Hradec Kralove, Novy Hradec Kralove · University Hospital Olomouc, Olomouc · Fakultni nemocnice Ostrava, Ostrava · Fakultni Nemocnice Plzen, Plzen 23 · Vseobecna fakultni nemocnice v Praze, Prague
Registry updated 2026-11-03
NCT07665450
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Fakultni nemocnice Brno, Brno · Fakultni nemocnice Hradec Kralove, Hradec Králové · Fakultni nemocnice Ostrava, Ostrava · Fakultni nemocnice Plzen, Pilsen · Vseobecna fakultni nemocnice v Praze, Prague · Fakultni nemocnice Kralovske Vinohrady, Prague
Registry updated 2026-11-03
NCT05519085
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Trial Treatment · Phase 3 · Celgene
Brno · Prague · Prague
Registry updated 2026-10-30
NCT06615479
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Trial Treatment · Phase 3 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Fakultni nemocnice Brno, Brno · Fakultni nemocnice Hradec Kralove, Hradec Králové · Fakultni nemocnice Ostrava, Ostrava · Vseobecna fakultni nemocnice v Praze, Prague
Registry updated 2026-10-29
NCT05623020
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Trial Treatment · Phase 3 · Pfizer
Fakultni nemocnice Brno, Brno · University Hospital Olomouc, Olomouc · Vseobecna fakultni nemocnice v Praze, Prague
Registry updated 2026-10-27
NCT04910568
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 1 · Genentech, Inc.
Fakultni nemocnice Ostrava, Ostrava
Registry updated 2026-10-20
2025-523815-12-00
A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Cilag International
Fakultni nemocnice Brno, Brno · Fakultni nemocnice Hradec Kralove, Hradec Králové · Fakultni nemocnice Ostrava, Ostrava · Fakultni Nemocnice Plzen, Plzen 23 · Vseobecna fakultni nemocnice v Praze, Prague · Fakultni nemocnice Kralovske Vinohrady, Prague
Registry updated 2026-10-19
NCT05669989
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Trial Treatment · Phase 2 · Sanofi
Brno · Ostrava · Prague
Registry updated 2026-10-15
NCT05735704
Early Detection and Screening of Hematological Malignancies - SANGUINE
Research · JaxBio Ltd
Fakultni nemocnice Olomouc FNOL, Olomouc
Registry updated 2026-10-15
2026-526654-14-01
A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Trial Treatment · Phase 3 · Janssen Cilag International
Fakultni nemocnice Brno, Brno · Fakultni nemocnice Hradec Kralove, Hradec Králové · Fakultni nemocnice Ostrava, Ostrava · Fakultni Nemocnice Plzen, Plzen 23 · Vseobecna fakultni nemocnice v Praze, Prague · Fakultni nemocnice Kralovske Vinohrady, Prague
Registry updated 2026-10-14
NCT07648264
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Trial Treatment · Phase 3 · CSL Behring
FH Hradec Kralove, Hradec Králové · FH Ostrova, Ostrova · Fakultni nemocnice Kralovske Vinohrady, Prague · UHKT Praha, Prague
Registry updated 2026-10-14
NCT06980480
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Trial Treatment · Phase 3 · Takeda
Fakultni nemocnice Ostrava, Ostrava · Vseobecna fakultni nemocnice v Praze, Prague
Registry updated 2026-10-13
NCT07555938
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Trial Treatment · Phase 3 · Hoffmann-La Roche
Fakultni nemocnice Brno, Brno · Fakultni nemocnice Hradec Kralove, Hradec Králové · Fakultni nemocnice Ostrava, Ostrava
Registry updated 2026-10-13
NCT05243797
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Trial Treatment · Phase 3 · European Myeloma Network B.V.
Fakultni nemocnice Brno, Brno · Fakultni Nemocnice Hradec Kralove, Novy Hradec Kralove · University Hospital Olomouc, Olomouc · Fakultni nemocnice Ostrava, Ostrava · Fakultni Nemocnice Plzen, Plzen 23 · Vseobecna fakultni nemocnice v Praze, Prague
Registry updated 2026-10-07
NCT07582432
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Trial Treatment · Phase 3 · Grifols Biologicals, LLC
Fakultni nemocnice Ostrava, Ostrava · Fakultni Nemocnice Plzen, Plzen 23 · Fakultní Nemocnice Královské Vinohrady, Praha 10
Registry updated 2026-10-01
NCT07518186
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Fakultni nemocnice Brno, Brno · FN Hradec Kralove, Hradec Králové · Fakultni nemocnice Ostrava, Ostrava · FN Plzen, Plzen-Lochotin · VFN Praha, Prague
Registry updated 2026-09-25
NCT05020236
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Trial Treatment · Phase 3 · Pfizer
Fakultni nemocnice Brno, Brno · Fakultni Nemocnice Hradec Kralove, Novy Hradec Kralove · University Hospital Olomouc, Olomouc · Fakultni nemocnice Ostrava, Ostrava · Fakultni Nemocnice Plzen, Plzen 23 · Vseobecna fakultni nemocnice v Praze, Prague
Registry updated 2026-08-24
NCT06152575
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Trial Treatment · Phase 3 · Pfizer
Fakultni nemocnice Brno, Brno · University Hospital Olomouc, Olomouc · Fakultní Nemocnice Královské Vinohrady, Prague 10 · Vseobecna Fakultni Nemocnice V Praze, Prague 2
Registry updated 2026-08-24
2025-525105-20-00
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Trial Treatment · Phase 1/2 · AbbVie Deutschland GmbH & Co. KG
Fakultni nemocnice Brno, Brno · Fakultni nemocnice Ostrava, Ostrava
Registry updated 2026-07-15
NCT06679101
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Trial Treatment · Phase 3 · GlaxoSmithKline
Fakultni nemocnice Ostrava, Ostrava · Fakultni nemocnice Kralovske Vinohrady, Prague
Registry updated 2026-04-22
NCT06932562
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
Trial Treatment · Phase 3 · European Myeloma Network B.V.
Fakultni nemocnice Brno, Brno · Fakultni nemocnice Hradec Kralove, Hradec Králové · University Hospital Olomouc, Olomouc · Fakultni nemocnice Ostrava, Ostrava · Fakultni Nemocnice Plzen, Plzen 23
Registry updated 2026-03-25
NCT05879757
Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency
Research · Takeda
Fakultni nemocnice Plzen, Pilsen · Vseobecna Fakultni Nemocnice, Prague
Registry updated 2026-02-18
NCT06237803
European Myeloma Network (EMN) Sample Project
Research · European Myeloma Network B.V.
Nemocnice Havířov, Havířov · Nemocnice Nový Jičín, Nový Jičín · Fakultní nemocnice, Olomouc · Slezská nemocnice, Opava · Fakutni nemocnice Ostrava, Ostrava · Nemocnice Pelhrimov, Pelhřimov · Všeobecná Fakultní nemocnice v Praz, Prague
Registry updated 2025-12-03

All Multiple myeloma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error